VC-backed Allogene Therapeutics goes public
South San Francisco-based Allogene Therapeutics, a biotech company focused on cancer treatment, has raised $324 million after pricing its 18 million shares at $18 per share. The stock began trading October 11, 2018 on the NASDAQ under the ticker symbol "ALLO." Goldman Sachs, J.P. Morgan Securities LLC, Cowen and Company and Jefferies LLC are the lead underwriters. Allogene's pre-IPO backers included Vida Ventures.
11 October 2018•2 mins read
